A detailed history of Smith, Salley & Associates transactions in Novartis Ag stock. As of the latest transaction made, Smith, Salley & Associates holds 3,436 shares of NVS stock, worth $337,930. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,436
Previous 3,436 -0.0%
Holding current value
$337,930
Previous $365,000 8.22%
% of portfolio
0.03%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$92.57 - $107.37 $9,719 - $11,273
105 Added 3.15%
3,436 $365,000
Q1 2024

May 02, 2024

BUY
$95.27 - $108.47 $9,336 - $10,630
98 Added 3.03%
3,331 $322,000
Q4 2023

Jan 24, 2024

SELL
$92.27 - $101.54 $276 - $304
-3 Reduced 0.09%
3,233 $326,000
Q3 2023

Oct 27, 2023

SELL
$94.73 - $105.13 $284 - $315
-3 Reduced 0.09%
3,236 $329,000
Q2 2023

Aug 04, 2023

BUY
$92.52 - $104.91 $30,346 - $34,410
328 Added 11.27%
3,239 $326,000
Q1 2023

May 03, 2023

SELL
$80.03 - $92.81 $2,881 - $3,341
-36 Reduced 1.22%
2,911 $267,000
Q4 2022

Feb 03, 2023

SELL
$75.55 - $92.52 $2.26 Million - $2.76 Million
-29,861 Reduced 91.02%
2,947 $267,000
Q3 2022

Nov 01, 2022

BUY
$74.61 - $87.26 $12,683 - $14,834
170 Added 0.52%
32,808 $2.49 Million
Q2 2022

Aug 01, 2022

SELL
$80.52 - $93.75 $574,188 - $668,531
-7,131 Reduced 17.93%
32,638 $2.76 Million
Q1 2022

May 10, 2022

BUY
$80.11 - $90.62 $74,822 - $84,639
934 Added 2.41%
39,769 $3.49 Million
Q4 2021

Feb 10, 2022

SELL
$79.7 - $88.13 $83,366 - $92,183
-1,046 Reduced 2.62%
38,835 $3.4 Million
Q3 2021

Nov 05, 2021

BUY
$81.78 - $95.14 $138,453 - $161,072
1,693 Added 4.43%
39,881 $3.26 Million
Q2 2021

Aug 09, 2021

BUY
$85.24 - $94.15 $48,757 - $53,853
572 Added 1.52%
38,188 $3.48 Million
Q1 2021

Apr 30, 2021

BUY
$83.5 - $98.47 $69,388 - $81,828
831 Added 2.26%
37,616 $3.22 Million
Q4 2020

Jan 28, 2021

SELL
$78.07 - $94.43 $20,376 - $24,646
-261 Reduced 0.7%
36,785 $3.47 Million
Q3 2020

Nov 05, 2020

BUY
$82.14 - $91.0 $19,302 - $21,385
235 Added 0.64%
37,046 $3.22 Million
Q2 2020

Aug 04, 2020

BUY
$80.93 - $91.1 $156,842 - $176,551
1,938 Added 5.56%
36,811 $3.22 Million
Q1 2020

Apr 24, 2020

SELL
$70.67 - $99.01 $88,125 - $123,465
-1,247 Reduced 3.45%
34,873 $2.88 Million
Q4 2019

Jan 27, 2020

BUY
$84.35 - $95.37 $15,436 - $17,452
183 Added 0.51%
36,120 $3.42 Million
Q3 2019

Oct 30, 2019

BUY
$85.54 - $94.26 $175,784 - $193,704
2,055 Added 6.07%
35,937 $3.12 Million
Q2 2019

Jul 12, 2019

SELL
$75.4 - $92.8 $133,156 - $163,884
-1,766 Reduced 4.95%
33,882 $3.09 Million
Q1 2019

May 03, 2019

BUY
$75.32 - $86.15 $62,666 - $71,676
832 Added 2.39%
35,648 $3.43 Million
Q4 2018

Feb 05, 2019

SELL
$73.66 - $82.02 $75,648 - $84,234
-1,027 Reduced 2.87%
34,816 $2.99 Million
Q3 2018

Nov 06, 2018

SELL
$66.94 - $77.43 $137,227 - $158,731
-2,050 Reduced 5.41%
35,843 $3.09 Million
Q2 2018

Aug 10, 2018

BUY
$64.91 - $73.36 $43,944 - $49,664
677 Added 1.82%
37,893 $2.86 Million
Q1 2018

May 09, 2018

BUY
$70.39 - $84.15 $34,631 - $41,401
492 Added 1.34%
37,216 $3.01 Million
Q4 2017

Feb 12, 2018

BUY
$72.33 - $77.64 $54,536 - $58,540
754 Added 2.1%
36,724 $3.08 Million
Q3 2017

Nov 02, 2017

BUY
$74.14 - $77.27 $2.67 Million - $2.78 Million
35,970
35,970 $3.09 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $212B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Smith, Salley & Associates Portfolio

Follow Smith, Salley & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Salley & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Salley & Associates with notifications on news.